<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063033</url>
  </required_header>
  <id_info>
    <org_study_id>0290-19 RMB</org_study_id>
    <nct_id>NCT04063033</nct_id>
  </id_info>
  <brief_title>IV Iron in Acute Decompensated Heart Failure</brief_title>
  <official_title>Randomized Bilnded Controlled Trial Comparing The Effect of IV Sodium Ferric Gluconate Complex (FERRLECIT R) on Outcome Patients Admitted Due To Acute Decompansated Heart Failure With Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims Compare the effect of addition of IV FERRLECITR (ferric gluconate) to standard
      therapy to standard therapy alone (without any IV iron treatment) in patients admitted with
      acute decompensated heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomisation to two groups, One receiving IV Iron on top of standard therapy while admitted to the hospital and the other receiving only standard therapy for acute heart failure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Two cardiologists will examine the participants after 12 and 24 weeks and evaluate functional status and volume status.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Capacity</measure>
    <time_frame>12 and 24 Weeks</time_frame>
    <description>The functional capacity will be evaluated by the 6 minute walk test at baseline,12 weeks and 24 weeks follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Change in NYHA from baseline to 12 and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of all cause mortality up to 1 year followup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations due to heart failure.</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of hospitalisations due to heart failure up to 1 year followup</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>IV Iron treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered IV Iron for 3-5 days. 125 mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No IV Iron treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard treatment for heart failure without IV Iron.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV iron - Sodium Ferric Gluconate Complex</intervention_name>
    <description>IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.</description>
    <arm_group_label>IV Iron treatment</arm_group_label>
    <other_name>IV Ferrlecit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients admitted due to acute decompensated heart failure to internal medicine
             department H or cardiology department.

               -  Must meet two of the following criteria :

                    -  NT pro BNP &gt; 300 pg/ml (&gt;800 pg/ml in the presence of Atrial Fibrillation).

                    -  Peripheral pitting edema,

                    -  Jugular Venous Distention,

                    -  pulmonary edema/congestion according to physical examination or Chest X-ray.

               -  IV furosemide treatment on admission to ER or internal ward/cardiology
                  department.

          2. Hb level 8-14 mg/dl on admission.

          3. Iron stores: Ferritin &lt;100 or Ferritin 100-300 and Transferrin saturation &lt; 20%.

          4. No evidence of active bleeding.

          5. Patient provided informed consent.

        Exclusion Criteria:

          1. Cardiogenic shock or any other condition requiring IV vasopressors.

          2. Previous allergy or anaphylaxis due to IV Iron.

          3. Active malignancy undergoing treatment.

          4. Status post major surgery involving substantial blood loss in the past 3 months.

          5. Indication for Blood transfusion.

          6. Infection indicating IV antibiotics.

          7. History of acquired iron overload; known haemochromatosis or first relatives with
             hemochromatosis; and allergic disorders (asthma, eczema, and anaphylactic reactions).

          8. hemolytic anemia.

          9. History of chronic liver disease and/or alanine transaminase (ALT) or aspartate
             transaminase (AST) &gt;3 times the upper limit of the normal range; chronic lung disease;
             myelodysplastic disorder; and known HIV/AIDS disease.

         10. Recipient of immunosuppressive therapy or renal dialysis. History of erythropoietin,
             IV iron therapy, and blood transfusion in previous 30 days.

         11. Unstable angina pectoris, as judged by the investigator; severe uncorrected valvular
             disease or left ventricular outflow obstruction; obstructive cardiomyopathy;
             uncontrolled fast atrial fibrillation or flutter (heart rate &gt;110 beats per minute
             [bpm]); uncontrolled symptomatic brady- or tachyarrhythmias.

         12. Musculoskeletal limitation that, in the judgement of the investigator, would impair
             cardiopulmonary exercise testing.

         13. Pregnant or breastfeeding.

         14. Inability to comprehend study protocol.

         15. Parallel participation in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 18, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Erez Marcusohn MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

